BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sárl (Nasdaq:CELG) today announced preliminary data were presented from an international study of single agent REVLIMID in relapsed/refractory non-Hodgkin’s lymphoma (NHL-003, Abstract #8509). The data was presented at the 44th Annual American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
